**CSRD Roadmap: Accelerating the Translation of New Medications for Veterans with PTSD**

**Discovery Phase:**
- Increase the number of compounds being studied, from 2 in 2016, to 6 in 2018, to 12 in 2020.

**Confirmatory Phase:**
- Narrow focus on compounds with positive results from 2020 forward.

**Desired Outcomes:**
- Evidence-based clinical practice changes
  - Clinical Practice Guidelines
  - VHA Formulary
  - FDA Labeling

**Overall Goal:**
- Improvements in Symptoms and Function in Veterans with PTSD

---

**TIMELINE:**
- 2016
  - BLRD Target Development
- 2018
  - DoD Adaptive Trial
- 2020
  - Definitive trials focused on labeling
  - Combination pharmacology
  - Adjunctive pharmacology w/ evidence based psychotherapies
  - Precision medicine, predictive markers of response
  - Adaptive trials / sequencing treatment studies
- 2024
  - Implementation studies
  - De-implementation studies
  - QUERI rollout

**VA Studies:**
- Mifepristone (NCT00833339)
- Prazosin (NCT00532493)
- Doxazosin (NCT02500602)
- Prazosin (NCT03539614)
- Suvorexant (NCT03642028)
- Ketamine (NCT02655692)
- Cannabidiol (NCT03518801)
- DHEA (NCT03491097)

**Non-VA Studies:**
- Losartan

**LEGEND:**
- **Funded**
- **In Planning**
- **Future**
- **PPI**

**Activities:**
- 1st PPI Industry Day
- PPI Announcement
- Paper in Biol Psych
- 1st PPI Workshop
- DoD State of the Science Summit
- 2nd PPI Workshop (May 2019)
- ISTSS Workshop
- BLRD Field-Based Meeting: Target Development
- CVB Rapid Dx
- New RFAs
  - BLRD: Target Development
  - CSRD: Drug Gaps